VIVIAN BLANCO: Open Payments
NPI 1871165852 · SCHENECTADY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,825 in 84 payments from 13 companies in 2025. Trend: 2023 $968 · 2024 $1,830 · 2025 $2,825
Food & beverage: $2,825
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 11 | $457 |
| Neurocrine BioSciences, Inc. | 11 | $432 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $387 |
| ABBVIE INC. | 14 | $384 |
| Teva Pharmaceuticals USA, Inc. | 6 | $318 |
| Novo Nordisk Inc | 2 | $239 |
| E.R. Squibb & Sons, L.L.C. | 7 | $163 |
| Vanda Pharmaceuticals Inc. | 7 | $135 |
| Janssen Pharmaceuticals, Inc | 4 | $112 |
| Axsome Therapeutics, Inc. | 2 | $52 |
Products named: INGREZZA, CAPLYTA, VRAYLAR, LYBALVI, Wegovy, COBENFY, UZEDY, AUSTEDO XR.
Industry payments across NY — which companies pay providers there.
